QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients

Abstract

Thioridazine cardiotoxicity has been associated with a prolonged heart-rate corrected QT (QTc) interval. However, no systematic studies have been performed on patients at therapeutic doses. The present study aimed to evaluate the influence of dose and plasma concentration of thioridazine and CYP2D6 enzyme status on the QTc interval in psychiatric patients. Sixty-five Spanish European psychiatric patients receiving thioridazine antipsychotic monotherapy were studied. The plasma levels of thioridazine and its metabolites were determined by high-performance liquid chromatography. All patients were phenotyped for CYP2D6 activity with debrisoquine during treatment. Thirty-five patients (54%) had a QTc interval over 420 ms. The lengthening of QTc interval was correlated with plasma concentration (p< 0.05) and daily dose (p < 0.05) of thioridazine. CYP2D6 enzyme hydroxylation capacity, evaluated by debrisoquine metabolic ratio (MR) (p < 0.05) and thioridazine/mesoridazine ratio (p < 0.05), was also correlated with QTc intervals. The present study shows the relationship between QTc interval lengthening among psychiatric patients treated at therapeutical doses with the dose and the plasma concentration of thioridazine. Since debrisoquine MR has been shown to be correlated with the QTc intervals, CYP2D6 enzyme hydroxylation capacity might be relevant in determining the risk for QTc interval lengthening. Patients with impaired CYP2D6 enzyme activity due to enzyme inhibition by thioridazine might be more prone to increased risk of sudden death due to torsade de pointes type cardiac dysrhythmia.

Keywords

CYP2D6 debrisoquine QTc lengthening thioridazine

Get full access to this article

View all access options for this article.

References

Buckley N A , Whyte I M , Dawson A H (1995) Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 33: 199–204

Carrillo J A , Ramos S I , Herraiz A G , LLerena A , Agúndez J A , Berecz R , Duran M , Benítez J (1999) Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 19: 494–499

Dallaire S (2001) Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval. CMAJ 164: 91–95

Dillenkoffer R L , Gallant D M , Phillips J H (1972) Electrocardiographic evaluation of mesoridazine (Serentil). Curr Ther Res Clin Exp 14: 71–72

Drolet B , Vincent F , Rail J , Chahine M , Deschernes D , Nadeau S , Khalifa M , Hamelin B A , Turgeon J (1999) Thioridazine lengthens repolarization of cardiac ventricular myocites by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288: 1261–1268

Gury C , Canceil O , Iaria P (2000) Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 26: 62–72

Hale P W , Poklis A (1986) Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol Appl Pharmacol 86: 44–55

Hartigan-Go K , Bateman D N , Nyberg G , Martensson E , Thomas S H (1996) Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 60: 543–553

Haverkamp W , Breithardt G , Camm A J , Janse M J , Rosen M R , Antzelevitch C , Escande D , Franz M , Malik M , Moss A , Shah R (2000) The potential for QT prolongation and proarrhythmia by nonantiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 21: 1216–1231; simultaneously published in Cardiovasc Res 47: 219–233

10.

LLerena A , Herraiz A G , Cobaleda J , Johansson I , Dahl M L (1993) Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 54: 606–611

11.

LLerena A , Cobaleda J , Martínez C , Benítez J (1996) Interethnic differences in drug metabolism: influence of sex-related and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 21: 129–138

12.

LLerena A , Berecz R , De La Rubia A , Norberto M J , Benítez J (2000) The use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 22: 397–401

13.

LLerena A , Berecz R , De La Rubia A , Fernández-Salguero P , Dorado P (2001) Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6genotypes. Ther Drug Monit 23: 616–620

14.

Ray W A , Meredith S , Thapa P B , Meador K G , Hall K , Murray K T (2001) Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 58: 1161–1167

15.

Reilly J G , Ayis S A , Ferrier I N , Jones S J , Thomas S H (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355: 1048–1052

16.

Schneider LS (1993) Efficacy of treatment for geropsychiatric patients with severe mental illness. Psychopharmacol Bull 29: 501–524

17.

Schouten E G , Dekker J M , Meppelink P , Kok F J , Vandenbroucke J P , Pool J (1991) QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 84: 1516–1523

18.

Tristani-Firouzi M , Chen J , Mitcheson J S , Sanguinetti M C (2001) Molecular biology of K(+) channels and their role in cardiac arrhythmias (1). Am J Med 110: 50–59

19.

von Bahr C , Movin G , Nordin C , Liden A , Hammarlund-Udenaes M , Hedberg A , Ring H , Sjöqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 49: 234–240

20.

Warner J P , Barnes T R , Henry J A (1996) Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 93: 311–313